StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Artiva Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Artiva Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.86M, up 22.8% year over year. For fiscal 2025 it was $69.54M, up 38.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$69.54M+38.2%
FY2024Dec 31, 2024$50.33M+0.2%
FY2023Dec 31, 2023$50.25M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$21.93M+22.8%
Q1 FY2026Mar 31, 2026$19.31M+13.3%
Q4 FY2025Dec 31, 2025$16.99M+27.6%
Q3 FY2025Sep 30, 2025$17.63M+30.4%
Q2 FY2025Jun 30, 2025$17.86M+44.8%
Q1 FY2025Mar 31, 2025$17.05M+52.9%
Q4 FY2024Dec 31, 2024$13.32M+19.4%
Q3 FY2024Sep 30, 2024$13.52M+3.5%
Q2 FY2024Jun 30, 2024$12.33M+9.5%
Q1 FY2024Mar 31, 2024$11.16M–
Q4 FY2023Dec 31, 2023$11.15M–
Q3 FY2023Sep 30, 2023$13.07M–
Q2 FY2023Jun 30, 2023$11.26M–

More Artiva Biotherapeutics figures

See a number that looks wrong?